Case Report
Copyright ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Sep 16, 2023; 11(26): 6154-6158
Published online Sep 16, 2023. doi: 10.12998/wjcc.v11.i26.6154
Mepolizumab induced palmoplantar psoriasis: A case report
Fabio Artosi, Laura Diluvio, Martina Vultaggio, Elena Campione, Luca Bianchi
Fabio Artosi, Martina Vultaggio, Elena Campione, Department of Systems Medicine, University of Rome “Tor Vergata”, Rome 00133, Italy
Laura Diluvio, Department of Dermatology, Dermatology Unit, Policlinico Tor Vergata, Rome 00133 , Italy
Luca Bianchi, Department of Dermatology, University Roma Tor Vergata, Rome 00133, Italy
Author contributions: Artosi F and Diluvio L contributed to conceptualization; Campione E contributed to methodology; Artosi F and Diluvio L contributed to investigation; Artosi F, Diluvio L, and Vultaggio M contributed to data curation; Artosi F contributed to writing and original draft preparation; Diluvio L and Bianchi L contributed to writing review and editing.
Informed consent statement: Informed written consent was obtained from the patient for the publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest to disclose.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Fabio Artosi, MD, Academic Fellow, Doctor, Department of Systems Medicine, University of Rome “Tor Vergata”, 81 Viale Oxford, Rome 00133, Italy. fabio.artosi994@gmail.com
Received: March 14, 2023
Peer-review started: March 14, 2023
First decision: April 11, 2023
Revised: May 4, 2023
Accepted: May 24, 2023
Article in press: May 24, 2023
Published online: September 16, 2023
Processing time: 177 Days and 10.7 Hours
Core Tip

Core Tip: We report the case of a 59-year-old patient with severe asthma who developed palmar psoriasis after 6 mo from the initiation of treatment with a humanized monoclonal antibody directed against interleukin-5 (IL-5), mepolizumab. There are several case reports of psoriasis induced by dupilumab therapy in the literature, but this phenomenon has not yet been recognized with modulating IL-5R signalling. This article reports the pathogenetic hypotheses that may underlie this phenomenon.